Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis
Endocrine-Related Cancer · 2024
DOI: 10.1530/erc-23-0349 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2024. Verfasst von Katherine I Wolf und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Pheochromocytoma, Adrenal Gland Neoplasms, Paraganglioma. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Pheochromocytoma and paragangliomas (PPGLs) originate from the chromaffin cells of the adrenal medulla or neural crest progenitors outside the adrenal gland, respectively. The estimated annual incidence of PPGL is between 2.0 and 8.0/million adults. Minimal data exist on the impact of PPGL from the patient’s perspective. Therefore, a survey was adapted from a previously published study on gastroenteropancreatic neuroendocrine tumors to explore the voice of patients with PPGL and learn ways to improve clinical care while understanding the current gaps to direct future research. A self-reported online survey was available to patients with PPGL and those with genetic predisposition even without PPGL from June to July 2022. Survey questions captured sociodemographic and clinical characteristics, the diagnostic workup, treatment and monitoring, quality and access to care, and financial impact. Here, we report the most relevant findings on patient experience of disease burden following diagnosis. A total of 270 people responded, the majority of whom were from the USA (79%), Caucasian (88%), and female (81%). The results of this survey highlight the burden of disease on a patient’s daily life, resulting in moderate to severe financial distress, increased travel time to specialized facilities resulting in loss of work and wages, and significant delays in care. Respondents reported being unheard and unacknowledged. With a median time to diagnosis just over 2 years, the physical, mental, and emotional toll are substantial. Increasing access to PPGL specialists and centers could lead to faster diagnoses and better management, which may reduce the burden on both patients and healthcare centers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA.
- Pheo Para Alliance and Psychology Department, Brock University, St. Catharines, Ontario, Canada.
- Pheo Para Alliance, Alexandria, Virginia, USA.
- Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
- Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, and Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA.
ORCID-Profile: Lauren Fishbein
Zitieren
APA
Wolf, K. I., Rose-Krasnor, L., Alband, S., Lenders, J. W. M., & Fishbein, L. (2024). Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis. Endocrine-Related Cancer. https://doi.org/10.1530/erc-23-0349
Vancouver
Wolf KI, Rose-Krasnor L, Alband S, Lenders JWM, Fishbein L. Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis. Endocrine-Related Cancer. 2024. doi:10.1530/erc-23-0349
BibTeX
@article{Wolf2024,
author = {Wolf, Katherine I and Rose-Krasnor, Linda and Alband, Stephanie and Lenders, Jacques W M and Fishbein, Lauren},
title = {Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis},
journal = {Endocrine-Related Cancer},
year = {2024},
doi = {10.1530/erc-23-0349}
}
EUVIMED